Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00656032 · ClinicalTrials.gov registry record · Phase 2
Vitamin D, Insulin Resistance and Inflammation in ESRD
A Phase 2 study, sponsored by Vanderbilt University.
- Completed
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
NCT00656032 is a Phase 2 study that has completed, run by Vanderbilt University. The registered enrollment target is 12 participants.
The verdict
NCT00656032, a Phase 2 study, has completed, sponsored by Vanderbilt University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
Study Summary
The broad goal of this study is to understand the mechanisms by which Vitamin D receptor activation leads to changes in insulin signaling in advanced uremia. We hypothesize that 1,25-Dihydroxyvitamin D3 deficiency due to advanced chronic kidney disease leads to insulin resistance and that administration of a vitamin D3 analog will restore insulin sensitivity in End Stage Renal Disease patients.
Interventions
- OTHER paricalcitol
- OTHER cinacalcet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2008-04 |
| Est. Completion | 2010-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00656032
The ClinicalTrials.gov registry entry for NCT00656032 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt University, which has 430 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which paricalcitol is the first listed.
NCT00656032 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00656032 about?
NCT00656032 is a clinical study titled "Vitamin D, Insulin Resistance and Inflammation in ESRD". The broad goal of this study is to understand the mechanisms by which Vitamin D receptor activation leads to changes in insulin signaling in advanced uremia. We hypothesize that 1,25-Dihydroxyvitamin D3 deficiency due to advanced chronic kidney disease leads to insulin resistance and that administra...
What is the current status of trial NCT00656032?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2008-04. Estimated completion is 2010-01.
What interventions are being tested in trial NCT00656032?
The interventions under investigation include: paricalcitol (OTHER), cinacalcet (OTHER).
Who is sponsoring clinical trial NCT00656032?
This trial is sponsored by Vanderbilt University, which has 430 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.